Implementation of Cardiovascular Risk management for patients with Rheumatoïd Arthritis (I-CaRe)

Implementation of Cardiovascular Risk management for patients with Rheumatoïd Arthritis (I-CaRe) - I-CaRe

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON41344

Enrollment

3200

Registered

2010-12-13

Start date

2011-06-23

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiovascular disease and atherosclerosis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: patients who have the diagnosis rheumatoid arthritis according to the ACR classification criteria

Exclusion criteria

Exclusion criteria: no signed informed consent

Design outcomes

Primary

Measure	Time frame
The percentage of RA patients at baseline, 1, 2, 3, 4 and 5 years, participating in this implementation study and their assessed risk profile The calulated difference between 10-years cardiovascular mortality risk at baseline, 1, 2, 3, 4 and 5 years.	—

Secondary

Measure	Time frame
First we will assess the cardiovascular risk profile of all participating RA patients. Then we will calculate the percentages of patients with untreated hypertension, hypercholesterolemia and/or diabetes mellitus type 2 separately. The incidence of cardiovascular events, like angina pectoris, myocardial infarction, ischemic heart disease, heart failure, PCI, CABG, CVA, TIA, carotid-endarteriectomy, signs of periferal atherosclerosis. We will compare these incidence rates with the incidence rates of the CARRE study. The effect of antihypertenive medication and statins in RA patients after 1, 2, 3, 4 and 5 years of CV-RM. Compliance of lifestyle advices and prescribed medication Patients satisfaction with offered care, assessed with a questionnaire	—

Measure

Time frame

First we will assess the cardiovascular risk profile of all participating RA patients. Then we will calculate the percentages of patients with untreated hypertension, hypercholesterolemia and/or diabetes mellitus type 2 separately. The incidence of cardiovascular events, like angina pectoris, myocardial infarction, ischemic heart disease, heart failure, PCI, CABG, CVA, TIA, carotid-endarteriectomy, signs of periferal atherosclerosis. We will compare these incidence rates with the incidence rates of the CARRE study. The effect of antihypertenive medication and statins in RA patients after 1, 2, 3, 4 and 5 years of CV-RM. Compliance of lifestyle advices and prescribed medication Patients satisfaction with offered care, assessed with a questionnaire

—

Countries

Netherlands

Outcome results